XML 50 R40.htm IDEA: XBRL DOCUMENT
v3.21.2

Acquisitions - Estimated Useful Life and Fair Value (Detail) $ in Thousands | 9 Months Ended
--- | ---
Sep. 30, 2021 USD ($)
Avitide, Inc. |
Fair Value | $ 44,270
Polymem S.A. |
Fair Value | 25,680
ARTeSYN Biosolutions |
Fair Value | 67,390
Non Metallic Solutions |
Fair Value | $ 8,460
Customer Relationships [Member] | Avitide, Inc. |
Weighted Average Useful Life (in years) | 13 years
Fair Value | $ 23,310
Customer Relationships [Member] | Polymem S.A. |
Weighted Average Useful Life (in years) | 14 years
Fair Value | $ 17,234
Customer Relationships [Member] | ARTeSYN Biosolutions |
Weighted Average Useful Life (in years) | 17 years
Fair Value | $ 38,400
Customer Relationships [Member] | Non Metallic Solutions |
Weighted Average Useful Life (in years) | 14 years
Fair Value | $ 6,370
Developed Technology Rights [Member] | Avitide, Inc. |
Weighted Average Useful Life (in years) | 15 years
Fair Value | $ 19,610
Developed Technology Rights [Member] | Polymem S.A. |
Weighted Average Useful Life (in years) | 13 years
Fair Value | $ 7,545
Developed Technology Rights [Member] | ARTeSYN Biosolutions |
Weighted Average Useful Life (in years) | 15 years
Fair Value | $ 27,060
Developed Technology Rights [Member] | Non Metallic Solutions |
Weighted Average Useful Life (in years) | 12 years
Fair Value | $ 1,810
Trademark and tradename [Member] | Avitide, Inc. |
Weighted Average Useful Life (in years) | 18 years
Fair Value | $ 1,150
Trademark and tradename [Member] | Polymem S.A. |
Weighted Average Useful Life (in years) | 14 years
Fair Value | $ 557
Trademark and tradename [Member] | ARTeSYN Biosolutions |
Weighted Average Useful Life (in years) | 21 years
Fair Value | $ 1,630
Trademark and tradename [Member] | Non Metallic Solutions |
Weighted Average Useful Life (in years) | 15 years
Fair Value | $ 190
Noncompete Agreements [Member] | Avitide, Inc. |
Weighted Average Useful Life (in years) | 3 years
Fair Value | $ 200
Noncompete Agreements [Member] | Polymem S.A. |
Weighted Average Useful Life (in years) | 5 years
Fair Value | $ 344
Noncompete Agreements [Member] | ARTeSYN Biosolutions |
Weighted Average Useful Life (in years) | 3 years
Fair Value | $ 300
Noncompete Agreements [Member] | Non Metallic Solutions |
Weighted Average Useful Life (in years) | 3 years
Fair Value | $ 90

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_AvitideIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_PolymemSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_ArtesynBiosolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_NonMetallicSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |